166 related articles for article (PubMed ID: 23229133)
21. Pharmacological targeting of p53 through RITA is an effective antitumoral strategy for malignant pleural mesothelioma.
Di Marzo D; Forte IM; Indovina P; Di Gennaro E; Rizzo V; Giorgi F; Mattioli E; Iannuzzi CA; Budillon A; Giordano A; Pentimalli F
Cell Cycle; 2014; 13(4):652-65. PubMed ID: 24345738
[TBL] [Abstract][Full Text] [Related]
22. Survivin is highly expressed and promotes cell survival in malignant peritoneal mesothelioma.
Zaffaroni N; Costa A; Pennati M; De Marco C; Affini E; Madeo M; Erdas R; Cabras A; Kusamura S; Baratti D; Deraco M; Daidone MG
Cell Oncol; 2007; 29(6):453-66. PubMed ID: 18032822
[TBL] [Abstract][Full Text] [Related]
23. Assessment of signaling pathway inhibitors and identification of predictive biomarkers in malignant pleural mesothelioma.
Tranchant R; Quetel L; Montagne F; De Wolf J; Meiller C; De Koning L; Le Pimpec-Barthes F; Zucman-Rossi J; Jaurand MC; Jean D
Lung Cancer; 2018 Dec; 126():15-24. PubMed ID: 30527180
[TBL] [Abstract][Full Text] [Related]
24. Increased sensitivity to apoptosis upon endoplasmic reticulum stress-induced activation of the unfolded protein response in chemotherapy-resistant malignant pleural mesothelioma.
Xu D; Liang SQ; Yang H; Lüthi U; Riether C; Berezowska S; Marti TM; Hall SRR; Bruggmann R; Kocher GJ; Schmid RA; Peng RW
Br J Cancer; 2018 Jul; 119(1):65-75. PubMed ID: 29921948
[TBL] [Abstract][Full Text] [Related]
25. Gene expression profiling of homologous recombination repair pathway indicates susceptibility for olaparib treatment in malignant pleural mesothelioma in vitro.
Borchert S; Wessolly M; Schmeller J; Mairinger E; Kollmeier J; Hager T; Mairinger T; Herold T; Christoph DC; Walter RFH; Eberhardt WEE; Plönes T; Wohlschlaeger J; Aigner C; Schmid KW; Mairinger FD
BMC Cancer; 2019 Jan; 19(1):108. PubMed ID: 30700254
[TBL] [Abstract][Full Text] [Related]
26. Mithramycin Depletes Specificity Protein 1 and Activates p53 to Mediate Senescence and Apoptosis of Malignant Pleural Mesothelioma Cells.
Rao M; Atay SM; Shukla V; Hong Y; Upham T; Ripley RT; Hong JA; Zhang M; Reardon E; Fetsch P; Miettinen M; Li X; Peer CJ; Sissung T; Figg WD; De Rienzo A; Bueno R; Schrump DS
Clin Cancer Res; 2016 Mar; 22(5):1197-210. PubMed ID: 26459178
[TBL] [Abstract][Full Text] [Related]
27. ADP sensitizes ZL55 cells to the activity of cisplatin.
Muscella A; Cossa LG; Vetrugno C; Antonaci G; Marsigliante S
J Cell Physiol; 2019 Apr; 234(4):4409-4417. PubMed ID: 30144378
[TBL] [Abstract][Full Text] [Related]
28. MST1/Hippo promoter gene methylation predicts poor survival in patients with malignant pleural mesothelioma in the IFCT-GFPC-0701 MAPS Phase 3 trial.
Maille E; Brosseau S; Hanoux V; Creveuil C; Danel C; Bergot E; Scherpereel A; Mazières J; Margery J; Greillier L; Audigier-Valette C; Moro-Sibilot D; Molinier O; Corre R; Monnet I; Gounant V; Langlais A; Morin F; Levallet G; Zalcman G
Br J Cancer; 2019 Feb; 120(4):387-397. PubMed ID: 30739911
[TBL] [Abstract][Full Text] [Related]
29. Nintedanib Is Active in Malignant Pleural Mesothelioma Cell Models and Inhibits Angiogenesis and Tumor Growth
Laszlo V; Valko Z; Kovacs I; Ozsvar J; Hoda MA; Klikovits T; Lakatos D; Czirok A; Garay T; Stiglbauer A; Helbich TH; Gröger M; Tovari J; Klepetko W; Pirker C; Grusch M; Berger W; Hilberg F; Hegedus B; Dome B
Clin Cancer Res; 2018 Aug; 24(15):3729-3740. PubMed ID: 29724868
[No Abstract] [Full Text] [Related]
30. Taurolidine and povidone-iodine induce different types of cell death in malignant pleural mesothelioma.
Opitz I; Sigrist B; Hillinger S; Lardinois D; Stahel R; Weder W; Hopkins-Donaldson S
Lung Cancer; 2007 Jun; 56(3):327-36. PubMed ID: 17383050
[TBL] [Abstract][Full Text] [Related]
31. Preclinical studies of the proteasome inhibitor bortezomib in malignant pleural mesothelioma.
Gordon GJ; Mani M; Maulik G; Mukhopadhyay L; Yeap BY; Kindler HL; Salgia R; Sugarbaker DJ; Bueno R
Cancer Chemother Pharmacol; 2008 Apr; 61(4):549-58. PubMed ID: 17522864
[TBL] [Abstract][Full Text] [Related]
32. Sorafenib inhibits ERK1/2 and MCL-1(L) phosphorylation levels resulting in caspase-independent cell death in malignant pleural mesothelioma.
Katz SI; Zhou L; Chao G; Smith CD; Ferrara T; Wang W; Dicker DT; El-Deiry WS
Cancer Biol Ther; 2009 Dec; 8(24):2406-16. PubMed ID: 20038816
[TBL] [Abstract][Full Text] [Related]
33. Targeting glucosylceramide synthase induction of cell surface globotriaosylceramide (Gb3) in acquired cisplatin-resistance of lung cancer and malignant pleural mesothelioma cells.
Tyler A; Johansson A; Karlsson T; Gudey SK; Brännström T; Grankvist K; Behnam-Motlagh P
Exp Cell Res; 2015 Aug; 336(1):23-32. PubMed ID: 26004871
[TBL] [Abstract][Full Text] [Related]
34. Signal Transducer and Activator of Transcription 1 (STAT1) Knock-down Induces Apoptosis in Malignant Pleural Mesothelioma.
Arzt L; Halbwedl I; Gogg-Kamerer M; Popper HH
Pathol Oncol Res; 2017 Jul; 23(3):595-605. PubMed ID: 27987139
[TBL] [Abstract][Full Text] [Related]
35. Hypoxia Inducible Factor-1α Inhibition in Von Hippel Lindau-mutant Malignant Pleural Mesothelioma Cells.
Shukuya T; Oyanagi J; Serizawa M; Watanabe M; Yamamoto N; Koh Y
Anticancer Res; 2020 Apr; 40(4):1867-1874. PubMed ID: 32234874
[TBL] [Abstract][Full Text] [Related]
36. BIRC5 promoter SNPs do not affect nuclear survivin expression and survival of malignant pleural mesothelioma patients.
Hmeljak J; Erčulj N; Dolžan V; Kern I; Cör A
J Cancer Res Clin Oncol; 2011 Nov; 137(11):1641-51. PubMed ID: 21861135
[TBL] [Abstract][Full Text] [Related]
37. The inhibition of FGF receptor 1 activity mediates sorafenib antiproliferative effects in human malignant pleural mesothelioma tumor-initiating cells.
Pattarozzi A; Carra E; Favoni RE; Würth R; Marubbi D; Filiberti RA; Mutti L; Florio T; Barbieri F; Daga A
Stem Cell Res Ther; 2017 May; 8(1):119. PubMed ID: 28545562
[TBL] [Abstract][Full Text] [Related]
38. Durvalumab with first-line chemotherapy in previously untreated malignant pleural mesothelioma (DREAM): a multicentre, single-arm, phase 2 trial with a safety run-in.
Nowak AK; Lesterhuis WJ; Kok PS; Brown C; Hughes BG; Karikios DJ; John T; Kao SC; Leslie C; Cook AM; Pavlakis N; Briscoe K; O'Byrne KJ; Karapetis CS; Lam WS; Langford A; Yip S; Stockler MR
Lancet Oncol; 2020 Sep; 21(9):1213-1223. PubMed ID: 32888453
[TBL] [Abstract][Full Text] [Related]
39. Cisplatin-induced expression of Gb3 enables verotoxin-1 treatment of cisplatin resistance in malignant pleural mesothelioma cells.
Johansson D; Andersson C; Moharer J; Johansson A; Behnam-Motlagh P
Br J Cancer; 2010 Jan; 102(2):383-91. PubMed ID: 20010943
[TBL] [Abstract][Full Text] [Related]
40. Is survivin expression prognostic or predictive in malignant pleural mesothelioma?
Hmeljak J; Erčulj N; Dolžan V; Pižem J; Kern I; Kovač V; Cemažar M; Cör A
Virchows Arch; 2013 Mar; 462(3):315-21. PubMed ID: 23358691
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]